Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate-specific membrane antigen: current and future utility

A K Gregorakis1, E H Holmes, G P Murphy

  • 1Pacific Northwest Cancer Foundation, Northwest Hospital, Seattle, WA 98125, USA.

Seminars in Urologic Oncology
|March 21, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.

Current radiopharmaceuticals·2010
Same author

Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues.

Prostate cancer and prostatic diseases·2003
Same author

Fucosyltransferases: structure/function studies.

Glycobiology·2001
Same author

An amino acid region at the N-terminus of rat hepatoma alpha1-->2 fucosyltransferase modulates enzyme activity and interaction with lipids: strong preference for glycosphingolipids containing terminal Galbeta1-->3GalNAc-structures.

Biochemistry·2001
Same author

PSMA specific antibodies and their diagnostic and therapeutic use.

Expert opinion on investigational drugs·2001
Same author

Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).

Hybridoma·2000
Same journal

The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies.

Seminars in urologic oncology·2002
Same journal

Poor prognosis germ-cell tumors: An unresolved challenge.

Seminars in urologic oncology·2002
Same journal

Chemotherapy for good-risk germ-cell tumors.

Seminars in urologic oncology·2002
Same journal

Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors.

Seminars in urologic oncology·2002
Same journal

Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?

Seminars in urologic oncology·2002
Same journal

Controversies in the management of testicular seminoma.

Seminars in urologic oncology·2002
See all related articles

Prostate-specific membrane antigen (PSMA) shows promise as a novel biomarker for prostate cancer. Elevated PSMA levels aid in predicting treatment failure and disease prognosis, supporting its diagnostic and therapeutic potential.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Prostate cancer is a leading cause of cancer death in men.
  • Current diagnostic and prognostic markers for prostate cancer have limitations.
  • Prostate-specific membrane antigen (PSMA) is a potential new biomarker.

Purpose of the Study:

  • To evaluate prostate-specific membrane antigen (PSMA) as a diagnostic and therapeutic target for prostate cancer.
  • To review the current applications and potential of PSMA in prostate cancer management.

Main Methods:

  • Serum measurement of PSMA using immunocompetitive and Western blot assays.
  • Reverse transcriptase-polymerase chain reaction (RT-PCR) for detecting circulating prostate cancer cells.
  • Immunoscintigraphy using PSMA-targeted antibody conjugates (e.g., CYT-356).

Related Experiment Videos

  • Evaluation of PSMA in prostate cancer immunotherapy trials.

    • Main Results:

    • PSMA levels correlate with treatment failure prediction and disease prognosis.
    • RT-PCR assays for PSMA are effective in detecting circulating tumor cells.
    • PSMA-based immunoscintigraphy (ProstaScint) shows clinical value in detecting occult prostate cancer.
    • Early immunotherapy trials targeting PSMA have yielded promising results.

    Conclusions:

    • Prostate-specific membrane antigen (PSMA) is a highly promising target for both diagnostic and therapeutic strategies in prostate cancer.
    • PSMA's elevated expression in aggressive prostate cancers underscores its prognostic significance.
    • Further research and clinical trials are warranted to fully leverage PSMA's potential in managing prostate cancer.